Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Official Title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

Summary:

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Trial Description

Primary Outcome:

  • Progression-free survival (PFS)
  • Overall Survival (OS)
Secondary Outcome:
  • Overall Survival (OS)
  • Objective Response Rate (ORR)
  • Progression-free survival PFS
  • Progression-free survival at 18 months (PFS18)
  • Progression-free survival at 24 months (PFS24)
  • Time to death or distant metastasis (TTDM)
  • Proportion of patients alive at 24 months (OS24)
  • Proportion of patients alive at and 36 months (OS36)
  • Time from randomization to second progression (PFS2)
  • To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-C30 v3
  • To assess the PK of durvalumab and tremelimumab in blood (peak trough concentration)
  • Presence of anti-drug antibodies (ADA) for durvalumab and tremelimumab (confirmatory results: positive or negative)
  • PD-L1 expression in tumour and/or immune cells relative to response/efficacy outcomes (PFS, OS & ORR).
  • To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-LC13

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society